Skip to main content
Jinyu Bio-Technology Co.,Ltd. logo

Jinyu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 600201 ISIN · CNE000000Y37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,776 across all filing types
Latest filing 2023-08-21 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600201

About Jinyu Bio-Technology Co.,Ltd.

http://jinyubiotech.com/

Jinyu Bio-Technology Co., Ltd. focuses on the research, development, and manufacturing of veterinary biological products and pharmaceuticals. The company is a prominent supplier of animal vaccines, particularly specializing in Foot-and-Mouth Disease (FMD) vaccines, brucellosis vaccines, and solutions for swine and poultry diseases. It utilizes advanced biotechnology platforms, including large-scale suspension culture and high-efficiency purification processes, to produce high-titer, high-purity biologicals. The organization operates sophisticated research facilities and Biosafety Level 3 (P3) laboratories to support the development of diagnostic reagents and preventive treatments. Its operations center on enhancing animal health through scientific innovation, providing comprehensive disease control strategies for the global livestock industry and large-scale agricultural operations.

Recent filings

Filing Released Lang Actions
北京市嘉源律师事务所关于金宇生物技术股份有限公司2023年度向特定对象发行A股股票并在主板上市的法律意见书
Regulatory Filings
2023-08-21 Chinese
金宇生物技术股份有限公司最近一年的财务报告及其审计报告以及最近一期的财务报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" (Audit Report) for the fiscal year 2022 of 金宇生物技术股份有限公司. It contains detailed audit opinions, basis for audit opinions, key audit matters, responsibilities of management and auditors, and extensive financial statement notes. The content includes audit procedures, accounting policies, financial statement disclosures, and detailed notes on financial instruments and credit loss provisions. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. There is no indication that this is a mere announcement or certification. Therefore, this document fits the category of a standalone Audit Report / Information (AR) rather than a full Annual Report (10-K) or other categories. FY 2022
2023-08-21 Chinese
金宇生物技术股份有限公司向特定对象发行股票证券募集说明书（申报稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed "募集说明书（申报稿）" which translates to a "Prospectus (Filing Draft)" for a specific issuance of A shares by 金宇生物技术股份有限公司 (Jinyu Bio-Technology Co., Ltd.) in 2023. It includes extensive information about the issuance background, pricing, shareholders, use of proceeds, legal and regulatory compliance, and detailed company and industry information. The document is lengthy (15,000 characters) and contains substantive content about the capital raising, share issuance, and related corporate governance and financial details. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. It is not an announcement of a report publication, nor a full annual or interim report, nor a proxy or voting announcement. Therefore, the correct classification is CAP with high confidence.
2023-08-21 Chinese
金宇生物技术股份有限公司关于向特定对象发行A股股票申请获得上海证券交易所受理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the acceptance by the Shanghai Stock Exchange of the company's application for a specific issuance of A shares to targeted investors. It mentions the regulatory review process and the need for further approvals before implementation. The document is short (589 characters) and serves as a notification of the acceptance of the application, not the issuance itself or detailed financial data. This fits the category of Capital/Financing Update (CAP), which covers updates on fundraising and financing activities.
2023-08-21 Chinese
金宇生物技术股份有限公司关于股东股份解除质押的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement regarding the release of pledged shares by a significant shareholder (holding more than 5% of shares). It details the number of shares released from pledge, the shareholder's total holdings, and the status of pledged shares. There is no financial performance data, no discussion of financial results, no mention of annual or quarterly reports, nor any indication of management changes or legal proceedings. The document is a regulatory announcement about share pledge status, which fits the category of Regulatory Filings (RNS) as it does not fit into more specific categories like Major Shareholding Notification (MRQ) since it concerns pledge release rather than share ownership threshold crossing, nor does it fit into Share Issue/Capital Change (SHA) or Transaction in Own Shares (POS) as it is about pledge status. Therefore, the best classification is Regulatory Filings (RNS).
2023-07-20 Chinese
金宇生物技术股份有限公司关于2022年年度权益分派实施后调整向特定对象发行股票价格的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the adjustment of the stock issuance price to specific investors following the implementation of the 2022 annual equity distribution. It details the price adjustment calculation based on dividends paid and confirms that other issuance terms remain unchanged. The document references board meetings and shareholder meetings approving the issuance and price adjustment. It does not contain full financial statements or comprehensive financial analysis but focuses on the update of the issuance price and related corporate actions. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2023-06-30 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.